Nektar Therapeutics (NKTR)
73.69
-0.33
(-0.45%)
USD |
NASDAQ |
Aug 24, 16:00
73.70
+0.01
(+0.01%)
Pre-Market: 08:05
Nektar Therapeutics Gross Profit Margin (Quarterly) : 98.46% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 98.46% |
| March 31, 2026 | 98.61% |
| December 31, 2025 | 99.13% |
| September 30, 2025 | 98.34% |
| June 30, 2025 | 98.08% |
| March 31, 2025 | 95.93% |
| December 31, 2024 | 72.65% |
| September 30, 2024 | 81.62% |
| June 30, 2024 | 58.53% |
| March 31, 2024 | 60.56% |
| December 31, 2023 | 69.51% |
| September 30, 2023 | 48.51% |
| June 30, 2023 | 65.88% |
| March 31, 2023 | 67.31% |
| December 31, 2022 | 71.70% |
| September 30, 2022 | 78.95% |
| June 30, 2022 | 76.30% |
| March 31, 2022 | 78.59% |
| December 31, 2021 | 75.36% |
| September 30, 2021 | 78.69% |
| June 30, 2021 | 72.94% |
| March 31, 2021 | 75.66% |
| December 31, 2020 | 81.57% |
| September 30, 2020 | 81.45% |
| June 30, 2020 | 88.18% |
| Date | Value |
|---|---|
| March 31, 2020 | 88.01% |
| December 31, 2019 | 82.31% |
| September 30, 2019 | 83.14% |
| June 30, 2019 | 78.48% |
| March 31, 2019 | 80.72% |
| December 31, 2018 | 81.27% |
| September 30, 2018 | 82.77% |
| June 30, 2018 | 99.49% |
| March 31, 2018 | 82.52% |
| December 31, 2017 | 89.78% |
| September 30, 2017 | 96.29% |
| June 30, 2017 | 78.06% |
| March 31, 2017 | 75.21% |
| December 31, 2016 | 82.37% |
| September 30, 2016 | 80.64% |
| June 30, 2016 | 76.48% |
| March 31, 2016 | 84.94% |
| December 31, 2015 | 78.76% |
| September 30, 2015 | 88.72% |
| June 30, 2015 | 53.51% |
| March 31, 2015 | 92.24% |
| December 31, 2014 | 67.79% |
| September 30, 2014 | 93.06% |
| June 30, 2014 | 82.09% |
| March 31, 2014 | 60.01% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Elite Pharmaceuticals, Inc. | 40.61% |
| Daré Bioscience, Inc. | -294.5% |
| Aclaris Therapeutics, Inc. | 10.80% |
| Eton Pharmaceuticals, Inc. | 67.61% |
| Journey Medical Corp. | 61.58% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -48.20% |
| Return on Assets | -29.67% |
| Return on Invested Capital | -32.71% |
| Profit Margin (Quarterly) | -401.0% |
| Operating Margin (Quarterly) | -412.2% |
| Return on Net Operating Assets | -562.8% |